PXL065

PXL065 is a drug candidate for the treatment of nonalcoholic steatohepatitis. It is the deuterium-stabilized -enantiomer of pioglitazone which lacks PPARγ agonist activity and the associated side effects of weight gain and edema. PXL065 has demonstrated preclinical efficacy for both NASH and X-linked adrenoleukodystrophy. In 2022, it successfully completed a 9 month Phase 2 trial in biopsy-proven NASH patients where it met the primary endpoint for reduction in liver fat without weight gain or edema.
PXL065 was discovered and advanced to Phase 1 by DeuteRx, LLC using the strategy of deuterium-enabled chiral switching. In August 2018, PXL065 and a portfolio of deuterated thiazolidinediones was acquired by Poxel SA.